Pfizer Adds To Primary Care Pipeline Through Bayer Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
DGAT-1 inhibitor licensing agreement gives Pfizer a novel Phase I obesity and diabetes product.
You may also be interested in...
Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward
Bayer will buy Merck’s shares in Schering AG at €89 per share, or €3 more than the current bid.
Pfizer Sees Opportunity In Big Pharma’s Move To Specialty Products
CEO McKinnell says the move into specialty markets by competitors enables Pfizer to take advantage of openings in the primary care arena.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.